Company Encyclopedia
View More
name
Silence Therapeutics
SLN.US
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.
1.946 T
SLN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking123/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-64.30%E
    • Profit Margin-249.86%E
    • Gross Margin59.75%A
  • Growth ScoreB
    • Revenue YoY40.39%A
    • Net Profit YoY11.79%C
    • Total Assets YoY-35.34%E
    • Net Assets YoY-41.53%E
  • Cash ScoreB
    • Cash Flow Margin-40.02%D
    • OCF YoY40.39%A
  • Operating ScoreE
    • Turnover0.14E
  • Debt ScoreC
    • Gearing Ratio49.54%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

    European equities traded in the US as American Depositary Receipts rose 0.58% on the S&P Europe Select ADR Index. Notable gainers included Sequans Communications and Materialise, while Unilever and Novo Nordisk led the decliners. From the UK and Ireland, GSK and Vodafone Group were among the top gainers, whereas Silence Therapeutics and Mereo BioPharma Group were the main decliners.

    fidelity·
    US
    MREO
    +4.08%
    US
    SLN
    +12.64%
    US
    NVO
    +0.88%
    fidelity·
    US
    MREO
    +4.08%
    US
    SLN
    +12.64%
    US
    NVO
    +0.88%

    European Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading

    European equities traded in the US as American depositary receipts rose 0.11% on Thursday. Leading gainers included Telefonica (+3.9%) and TotalEnergies (+2.1%). Decliners were led by BioNTech (-6.1%) and Evaxion (-5%). UK and Ireland gainers included Silence Therapeutics (+2.4%) and Amarin (+1.3%), while Biodexa Pharmaceuticals (-8.5%) and Autolus Therapeutics (-6.3%) led decliners.

    fidelity·
    US
    TTE
    -0.21%
    US
    BNTX
    -0.75%
    US
    SLN
    +12.64%
    fidelity·
    US
    TTE
    -0.21%
    US
    BNTX
    -0.75%
    US
    SLN
    +12.64%

    Silence Therapeutics to Join Jefferies Global Healthcare Conference Fireside Chat

    Silence Therapeutics plc will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025. A live webcast of the event will be available on the company’s website. This announcement was originally published via Business Wire on November 12, 2025.

    Reuters·
    US
    SLN
    +12.64%
    Reuters·
    US
    SLN
    +12.64%

    Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position

    H.C. Wainwright's Patrick Trucchio reaffirmed a Buy rating for Silence Therapeutics, setting a price target of $75. The rating is based on the company's strong RNA interference pipeline, including the completion of enrollment in the Phase 2 SANRECO trial and readiness for Phase 3 with the zerlasiran program. Silence Therapeutics has a solid financial position, with a cash runway into 2028, supporting its clinical advancements. Trucchio, a top analyst, has an average return of 34.8% and a 52.26% success rate in the Healthcare sector.

    Tip Ranks·
    US
    SLN
    +12.64%
    Tip Ranks·
    US
    SLN
    +12.64%

    Silence Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 159 K

    LB filings·
    US
    SLN
    +12.64%
    LB filings·
    US
    SLN
    +12.64%
    © 2025 Longbridge｜Disclaimer